Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.31 |
| ▸ | HTR2B | P41595 | 3/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585197 | 0.84 | SLC6A2 (0.49) | SLC6A2SLC6A4HTR2CHTR2BSLC6A3 | |
| SCHEMBL2675321 | 0.68 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL587240 | 0.67 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL586670 | 0.67 | AVPR2 (0.40) | SSTR4SLC6A2SLC6A4 | |
| SCHEMBL7410443 | 0.66 | CHRNB2 (0.56) | CHRNB2CHRNA4 | |
| SCHEMBL2676099 | 0.66 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL586304 | 0.65 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL586669 | 0.65 | SLC6A2 (0.55) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2675976 | 0.65 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL7415122 | 0.65 | CHRNB2 (0.55) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417124-B1 | Serotonin and norepinephrine reuptake inhibitor | LILLY CO ELI (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8173821-B2 | Serotonin and norepinephrine reuptake inhibitor | ELI LILLY AND COMPANY (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2417124-A2 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | Eli Lilly and Company (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117979-A2 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | ELI LILLY AND COMPANY (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261762-A1 | SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITOR | SLC6A2, SLC6A4, TPH1 | SSTR4 339/4885SLC6A2 1/4885SLC6A4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.